|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Epithelial restitution and wound healing in inflammatory bowel disease显示文摘Inflammatory bowel disease is characterized by a chronic inflammation of the intestinal mucosa. The mucosal epithelium of the alimentary tract constitutes a key element of the mucosal barrier to a broad spectrum of deleterious substances present within the intestinal lumen including bacterial microorganisms, various dietary factors, gastrointestinal secretory products and drugs. In addition, this mucosal barrier can be disturbed in the course of various intestinal disorders including inflammatory bowel diseases. Fortunately, the integrity of the gastrointestinal surface epithelium is rapidly reestablished even after extensive destruction. Rapid resealing of the epithelial barrier following injuries is accomplished by a process termed epithelial restitution, followed by more delayed mechanisms of epithelial wound healing including increased epithelial cell proliferation and epithelial cell differentiation. Restitution of the intestinal surface epithelium is modulated by a range of highly divergent factors among them a broad spectrum of structurally distinct regulatory peptides, variously described as growth factors or cytokines. Several regulatory peptide factors act from the basolateral site of the epithelial surface and enhance epithelial cell restitution through TGF-β-dependent pathways. In contrast, members of the trefoil factor family (TFF peptides) appear to stimulate epithelial restitution in conjunction with mucin glycoproteins through a TGF-β-independent mechanism from the apical site of the intestinal epithelium. In addition, a number of other peptide molecules like extracellular matrix factors and blood clotting factors and also non- peptide molecules including phospholipids, short-chain fatty acids (SCFA), adenine nucleotides, trace elements and pharmacological agents modulate intestinal epithelial repair mechanisms. Repeated damage and injury of the intestinal surface are key features of various intestinaldisorders including inflammatory bowel diseases and require constant repair of the epithelium. Enhancement of intestinal repair mechanisms by regulatory peptides or other modulatory factors may provide future approaches for the treatment of diseases that are characterized by injuries of the epithelial surface. | Andreas Sturm Axel U Dignass | 2008 | World Journal of Gastroenterology2008，14，3： | 24 |
| 2 | Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis显示文摘 | Axel Dignass Rami Eliakim Fernando Magro Christian Maaser Yehuda Chowers Karel Geboes Gerassimos Mantzaris Walter Reinisch Jean-Frederic Colombel Severine Vermeire Simon Travis James O. Lindsay Gert Van Assche | 2012 | Journal of Crohn’s and Colitis2012，，10： | 12 |
| 3 | The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Definitions and diagnosis显示文摘 | Gert Van Assche Axel Dignass Julian Panes Laurent Beaugerie John Karagiannis Mathieu Allez Thomas Ochsenkühn Tim Orchard Gerhard Rogler Edouard Louis Limas Kupcinskas Gerassimos Mantzaris Simon Travis Eduard Stange | 2009 | Journal of Crohn’s and Colitis2009，，1： | 10 |
| 4 | Chronic intestinal failure and short bowel syndrome in Crohn’s disease显示文摘Chronic intestinal failure(CIF)is a rare but feared complication of Crohn’s disease.Depending on the remaining length of the small intestine,the affected intestinal segment,and the residual bowel function,CIF can result in a wide spectrum of symptoms,from single micronutrient malabsorption to complete intestinal failure.Management of CIF has improved significantly in recent years.Advances in home-based parenteral nutrition,in particular,have translated into increased survival and improved quality of life.Nevertheless,60%of patients are permanently reliant on parenteral nutrition.Encouraging results with new drugs such as teduglutide have added a new dimension to CIF therapy.The outcomes of patients with CIF could be greatly improved by more effective prevention,understanding,and treatment.In complex cases,the care of patients with CIF requires a multidisciplinary approach involving not only physicians but also dietitians and nurses to provide optimal intestinal rehabilitation,nutritional support,and an improved quality of life.Here,we summarize current literature on CIF and short bowel syndrome,encompassing epidemiology,pathophysiology,and advances in surgical and medical management,and elucidate advances in the understanding and therapy of CIF-related complications such as catheter-related bloodstream infections and intestinal failure-associated liver disease. | Aysegül Aksan Karima Farrag Irina Blumenstein Oliver Schröder Axel U Dignass Jürgen Stein | 2021 | World Journal of Gastroenterology2021，27，24： | 4 |
| 5 | Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitis显示文摘AIM:To study the efficacy, safety, and feasibility of a granulocyte adsorptive type apheresis system for the treatment of patients with chronically active ulcerative colitis despite standard therapy.METHODS: An open label multicenter study was carried out in 39 patients with active ulcerative colitis (CAI6-8) despite continuous use of steroids (a minimum total dose of 400 mg prednisone within the last 4 wk).Patients received a total of five aphereses using a granulocyte adsorptive technique (Adacolumn(R), Otsuka Pharmaceutical Europe, UK). Assessments at wk 6 and during follow-up until 4 mo comprised clinical (CAI) and endoscopic (EI) activity index, histology, quality of life(IBDQ), and laboratory tests.RESULTS: Thirty-five out of thirty-nine patients were qualified for intent-to-treat analysis. After the apheresis treatment at wk 6, 13/35 (37.1%) patients achieved clinical remission and 10/35 (28.6%) patients had endoscopic remission (CAI<4, EI<4). Quality of life (IBDQ) increased significantly (24 points, P<0.01)at wk 6. Apheresis could be performed in all but one patient. Aphereses were well tolerated, only one patient experienced anemia.CONCLUSION: In patients with steroid refractory ulcerative colitis, five aphereses with a granulocyte/monocyte depleting filter show potential short-term efficacy. Tolerability and technical feasibility of the procedure are excellent. | Wolfgang Kruis Axel Dignass Elisabeth Steinhagen-Thiessen Julia Morgenstern Joachim M(o|¨)ssner Stephan Schreiber Maurizio Vecchi Alberto Malesci Max Reinshagen Robert L(o|¨)fberg | 2005 | World Journal of Gastroenterology2005，11，44： | 4 |
| 6 | Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management显示文摘 | Axel Dignass James O. Lindsay Andreas Sturm Alastair Windsor Jean-Frederic Colombel Mathieu Allez Gert D’Haens André D’Hoore Gerassimos Mantzaris Gottfried Novacek Tom ?resland Walter Reinisch Miquel Sans Eduard Stange Severine Vermeire Simon Travis Gert | 2012 | Journal of Crohn’s and Colitis2012，，10： | 4 |
| 7 | Second European evidence-based consensus on the diagnosis and management of ulcerative colitis: Special situations显示文摘 | Gert Van Assche Axel Dignass Bernd Bokemeyer Silvio Danese Paolo Gionchetti Gabriele Moser Laurent Beaugerie Fernando Gomollón Winfried H?user Klaus Herrlinger Bas Oldenburg Julian Panes Francisco Portela Gerhard Rogler Jürgen Stein Herbert Tilg Simon Tra | 2012 | Journal of Crohn’s and Colitis2012，，： | 4 |
| 8 | The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Special situations显示文摘 | Gert Van Assche Axel Dignass Walter Reinisch C. Janneke van der Woude Andreas Sturm Martine De Vos Mario Guslandi Bas Oldenburg Iris Dotan Philippe Marteau Alessandro Ardizzone Daniel C. Baumgart Geert D’Haens Paolo Gionchetti Francisco Portela Boris Vuce | 2009 | Journal of Crohn’s and Colitis2009，，1： | 3 |
| 9 | Use of granulocyte/monocytapheresis in ulcerative colitis:A practical review from a European perspective显示文摘Half of the patients with ulcerative colitis require at least one course of systemic corticosteroids in their lifetime.Approximately 75%of these patients will also require immunosuppressive drugs(i.e.,thiopurines or biological agents)in the mid-term to avoid colectomy.Immunosuppressive drugs raise some concerns due to an increased risk of serious and opportunistic infections and cancer,particularly in elderly and co-morbid patients,underlining the unmet need for safer alternative therapies.Granulocyte/monocytapheresis(GMA),a CE-marked,non-pharmacological procedure for the treatment of ulcerative colitis(among other immune-mediated diseases),remains the only therapy targeting neutrophils,the hallmark of pathology in ulcerative colitis.GMA has proven its efficacy in different clinical scenarios and shows an excellent and unique safety profile.In spite of being a first line therapy in Japan,GMA use is still limited to a small number of centres and countries in Europe.In this article,we aim to give an overview from a European perspective of the mechanism of action,recent clinical data on efficacy and practical aspects for the use of GMA in ulcerative colitis. | Eugeni Domènech Joan-Ramon Grífols Ayesha Akbar Axel U Dignass | 2021 | World Journal of Gastroenterology2021，27，10： | 2 |
| 10 | Aktualisierte Leitlinie zur Diagnostik und Therapie der Colitis ulcerosa 2011 – Ergebnisse einer Evidenzbasierten Konsensuskonferenz显示文摘 | A. Dignass J. Prei? D. Aust F. Autschbach A. Ballauff G. Barretton B. Bokemeyer S. Fichtner-Feigl S. Hagel K. Herrlinger G. Jantschek A. Kroesen W. Kruis T. Kucharzik J. Langhorst M. Reinshagen G. Rogler D. Schleiermacher C. Schmidt S. Schreiber H. Schulz | 2011 | Z Gastroenterol2011，，09： | 2 |
| 11 | The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Current management显示文摘 | A. Dignass G. Van Assche J.O. Lindsay M. Lémann J. S?derholm J.F. Colombel S. Danese A. D’Hoore M. Gassull F. Gomollón D.W. Hommes P. Michetti C. O’Morain T. ?resland A. Windsor E.F. Stange S.P.L. Travis | 2010 | Journal of Crohn’s and Colitis2010，，1： | 2 |
| 12 | Intestinal barrier function 显示文摘 | Baumgart D C Dignass A U | 2002 | Curr Opin Ciin Nutr Metab2002，5，6： | 1 |
| 13 | Intestinal barrier function显示文摘 | Baumgart DC Dignass AU | 2002 | Curr Opin Clln Nutr Metab Care2002，5，7： | 1 |
| 14 | Fibroblast growth factors modulate intestinal epithelial cell growth and migration显示文摘 | Dignass AU Tsunekawa S Podolsky DK | 1994 | Gastroenterology1994，106，： | 1 |
| 15 | Second European ev- idence-based consensus on the diagnosis and management of ulcerative colitis:current management显示文摘 | Dignass A Lindsay J O Sturm A e t al | 2012 | J Crohns Coli- tis2012，6，10： | 1 |
| 16 | Successful therapy of refractory pyoderma gangrenosum and periorbital phlegmona with tacrolimus ( FKS06 ) in ulcerative colitis 显示文摘 | Baumgart DC Wiedenmann B Dignass AU | 2004 | Inflamm Bowel Dis2004，10，4： | 1 |
| 17 | Hepatocy te growth factor/scatter factor modulates intestinal epithelial cell proliferation and migration 显示文摘 | Dignass AU Lynch-Devaney K Podolsky DK | 1994 | Biochem Biophys Res Commun1994，202，2： | 1 |
| 18 | Second European evi- dence-based consensus on the diagnosis and management of ul- cerative colitis part 2:current management 显示文摘 | Dignass A Lindsay JO Sturm A | 2012 | J Crohns Colitis2012，6，10： | 1 |
| 19 | Factor XIII modulates intestinal epithelial wound healing in vitro 显示文摘 | Cario E Goebell H Dignass A U | 1999 | Scand J Gastroenlerol1999，34，6： | 1 |
| 20 | The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis显示文摘 | Van Assche G Dignass A Panes J | 2010 | J Crohns Colitis2010，4，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员